Atrial fibrillation and stroke: Elucidating a newly discovered risk factor

American Journal of Cardiology

Volumn 80, Issue 4 C, 1997, Pages

  Giardina, Elsa Grace V ^a  

^a The New York Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT THERAPY; ARTIFICIAL HEART PACEMAKER; CATHETER ABLATION; CONFERENCE PAPER; CORRELATION FUNCTION; HEART ATRIUM FIBRILLATION; HIGH RISK POPULATION; HUMAN; PRIORITY JOURNAL; RISK FACTOR; STROKE;

ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; BUNDLE OF HIS; CARDIAC OUTPUT, LOW; CATHETER ABLATION; CEREBROVASCULAR DISORDERS; CHRONIC DISEASE; CLINICAL TRIALS; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; FOLLOW-UP STUDIES; HUMANS; INTRACRANIAL EMBOLISM AND THROMBOSIS; NATIONAL INSTITUTES OF HEALTH (U.S.); PACEMAKER, ARTIFICIAL; PRACTICE GUIDELINES; RISK; RISK FACTORS; UNITED STATES;

EID: 0030801306     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00580-8     Document Type: Conference Paper

References (42)

1. Bialy D, Lehmann MH, Schumacher DN, Steinman RT, Meissner MD. Hospitalization for arrhythmias in the United States: importance of atrial fibrillation. (Abstr.). J Am Coll Cardiol. 19:1992;41A.
2. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA. 271:1994;840-844.
3. Golzari H, Cebul R, Bahler RC. Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy. Ann Intern Med. 125:1996;311-323.
4. Prystowsky EN, Benson W Jr, Fuster V, Hart RG, Kay GN, Myerburg RJ, Naccarelli GV, Wyse DG. Management of patients with atrial fibrillation: a statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation. 93:1996;1262-1277.
5. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Intern Med. 147:1987;1561-1564.
6. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 22:1991;983-988.
7. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol. 74:1994;236-241.
8. Kannel W, Abbott RD, Savage DD, McNamara PM. Epidemiological features of chronic atrial fibrillation: the Framingham Study. N Engl J Med. 306:1982;1018-1022.
9. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 154:1994;1449-1457.
10. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation. 84:1991;527-539.
11. Brand FN, Abbott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation: 30-year follow-up in the Framingham Study. JAMA. 254:1985;3449-3453.
12. Kopecky SL, Gersh BJ, McGoon MD, Whisnant JP, Holmes DR Jr, Ilstrup DM, Frye RL. The natural history of lone atrial fibrillation population-based study over three decades. N Engl J Med. 317:1987;669-674.
13. Benjamin EJ, D'Agostino RB, Belanger AJ, Wolf PA, Levy D. Left atrial size and the risk of stroke and death: the Framingham Heart Study. Circulation. 92:1995;835-841.
14. Manning WJ, Silverman DI, Gordon SPF, Krumholz HM, Doublas PS. Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi. N Engl J Med. 328:1993;750-755.
15. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet. 1:1989;175-179.
16. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med. 323:1990;1505-1511.
17. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol. 18:1991;349-355.
18. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause-Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJ. Warfarin in the prevention of stroke associated with non-valvular atrial fibrillation (SPINAF). N Engl J Med. 32:1992;1406-1412.
19. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 335:1996;540-546.
20. Adjusted dose warfarin versus low-intensity, fixed dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet. 348:1996;633-638.
21. Optimal oral anticoagulant therapy in patients with non-rheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med. 33:1995;5-10.
22. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II study. Lancet. 343:1994;687-691.
23. Miller VT, Rothrock JF, Pearce LA, Feinberg WM, Hart RG, Anderson DC. Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism. Neurology. 43:1993;32-36.
24. Third American College of Chest Physicians Conference on Antithrombotic Therapy. Chest. 102:1992;303S-305S.
25. Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to DC electrical cardioversion of atrial fibrillation. Am J Cardiol. 23:1969;208-215.
26. Goldman MJ. The management of chronic atrial fibrillation: indications and method of conversion to sinus rhythm. Prog Cardiovasc Dis. 2:1960;465-479.
27. Van Gelder IC, Crijns HJ, Van Gilst WH, Verwer R, Lie KL. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol. 68:1991;41-46.
28. Brodsky MA, Allen BJ, Capparelli EV, Luckett CR, Morton R, Henry WL. Factors determining maintenance of sinus rhythm after chronic atrial fibrillation with left atrial dilation. Am J Cardiol. 63:1989;1065-1068.
29. Kinch JW, Davidoff R. Prevention of embolic events after cardioversion of atrial fibrillation: current and evolving strategies. Arch Intern Med. 155:1995;1353-1360.
30. Connolly SJ, Hoffert DL. Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. Am J Cardiol. 63:1989;817-819.
31. Horowitz LN, Spielman SR, Greenspan AM, Miontz GS, Morganroth J, Brown R, Brady PM, Kay HR. Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol. 6:1985;1402-1407.
32. Podrid PJ. Class I antiarrhythmic agents for therapy of atrial fibrillation. Herz. 18:1993;9-19.
33. Pritchett ELC, DaTorre SD, Platt ML, McCarville SE, Hougham AJ. Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: dose-response studies. J Am Coll Cardiol. 17:1991;297-303.
34. Falk RH, Knowlton AA, Bernard SA, Gotlieb NE, Battinelli NJ. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm: a randomized, double-blinded trial. Ann Intern Med. 106:1987;504-506.
35. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm: a meta-analysis of randomized clinical trials. Circulation. 82:1990;1106-1116.
36. Flaker GC, Black-Sheor JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation: the Stroke Prevention in Atrial Fibrillation investigators. J Am Coll Cardiol. 20:1992;527-532.
37. Echt DS, Liebson RP, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, Huther ML, Richardson DW. Mortality and morbidity in patients receiving encainide, flecainide or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med. 324:1991;781-788.
38. Scheinman MM, Morady F, Hess DS, Gonzalez R. Catheter-induced ablation of the atrioventricular junction to control refractory supraventricular arrhythmias. JAMA. 248:1982;851-855.
39. Williamson BD, Man KC, Daoud E, Niebauer M, Strickberger SA, Morady F. Radiofrequency catheter modification of atrioventricular conduction to control the ventricular rate during atrial fibrillation. N Engl J Med. 331:1994;910-917.
40. Murgatroyd FD, Slade AK, Sopher SM, Rowland E, Ward DE, Camm AJ. Efficacy and tolerability of transvenous low energy cardioversion of paroxysmal atrial fibrillation in humans. J Am Coll Cardiol. 25:1995;1347-1353.
41. Guiraudon GM, Campbell CS, Jones DL, McLellan DG, MacDonald JL. Combined sino-atrial node atrio-ventricular isolation: a surgical alternative to His bundle ablation in patients with atrial fibrillation. (Abstr.). Circulation. 72:((suppl III)):1985;220.
42. Cox JL, Schuessler RB, D'Agostino HJ Jr, Stone CM, Chang BC, Cain ME, Corr PB, Boineau JP. The surgical treatment of atrial fibrillation: III. Development of a definitive surgical procedure. J Thorac Cardiovasc Surg. 101:1991;569-583.